Articles
Search articles by year of publication.
Search articles by industry.
Industry
- Aerospace
- Agriculture
- Alcohol
- Apparel
- Automotive
- Biotechnology
- Crypto
- Digitalization
- E-commerce
- Education
- Education Technology
- Employee Ownership
- Energy
- Entertainment
- Entrepreneurship
- Fashion
- FinTech
- Finance
- Financial Services
- Food
- Gaming
- Government
- Grocery
- Healthcare
- Industrial
- Information Technology
- Infrastructure
- Interview
- Marijuana
- Media and Entertainment
- Metals and Mining
- Pharmaceuticals
- Power and Utilities
- Private Equity
- Product Strategy
- Products and Consumer Goods
- Professional Services
- Racing
- Real Estate
- Restaurant and Hospitality
- Retail
- Security
- Services
- Social Impact
- Social Media
- Software
- Space Exploration
- Sports
- Start-ups
- Sustainability
Pfizer: Pounds to Profits
To outpace competitors in the race to develop the first semaglutide weight-loss pill, Pfizer should partner with Kallyope.
Cost Plus Drugs: Prescription for Success
Cost Plus Drugs should acquire India based PharmEasy to grow internationally.
Teva: Don't Be so Generic
In the face of squeezed margins in the generics industry, Teva must diversify revenues into the nascent biosimilar space to remain profitable.
Gilead: Cultivating the Pipeline
In order to restore investor confidence and hedge legacy market downturns, Gilead needs to diversify into other channels of sustainable revenue generation to minimize volatility
The Biosimilar Onslaught
Pharmaceutical companies face huge revenue uncertainties after the loss of patent exclusivity; but not all is lost.
The Battle Over Your Genes
The ACLU v. Myriad Genetics suit and the issues raised by gene patents